EUVIMEDEUVIMED entdecken
Crossref

Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation

Nischal Ranganath, Zachary A Yetmar, Audrey R McCandless, Christina G Rivera, Brian D Lahr, Aaron J Tande, Aditya S Shah

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Nischal Ranganath und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Bacteremia, Anti-Infective Agents, Hematologic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the management of Gram‐negative bloodstream infection (GN‐BSI), short antimicrobial courses have been increasingly demonstrated to be non‐inferior to prolonged therapy, with lower risk of Clostridioides difficile infection (CDI) and emergence of multi‐drug resistant (MDR) organisms. However, immunocompromised hosts were excluded from these studies. We investigated outcomes of short (≤10 days), intermediate (11–14 days), and prolonged (≥15 days) antimicrobial durations for GN‐BSI in neutropenic patients.

Methods

A retrospective cohort study was conducted on neutropenic patients with monomicrobial GN‐BSI between 2018 and 2022. The primary outcome was a composite of all‐cause mortality and microbiologic relapse within 90 days after therapy completion. The secondary outcome was a composite of 90‐day CDI and development of MDR‐GN bacteria. Cox regression analysis with propensity score (PS) adjustment was used to compare outcomes between the three groups.

Results

A total of 206 patients were classified into short ( n = 67), intermediate ( n = 81), or prolonged ( n = 58) duration. Neutropenia was predominantly secondary to hematopoietic stem cell transplantation (48%) or hematologic malignancy (35%). The primary sources of infection included intra‐abdominal (51%), vascular catheter (27%), and urinary (8%). Most patients received definitive therapy with cefepime or carbapenem. No significant difference in the primary composite endpoint was observed for intermediate versus short (PS‐adjusted hazard ratio [aHR] 0.89; 95% confidence interval [95% CI] 0.39–2.03) or prolonged versus short therapy (PS‐aHR 1.20; 95% CI 0.52–2.74). There was no significant difference in the secondary composite endpoint of CDI or MDR‐GN emergence.

Conclusion

Our data suggest that short antimicrobial courses had comparable 90‐day outcomes as intermediate and prolonged regimens for GN‐BSI among immunocompromised patients with neutropenia. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationBacteremiaAnti-Infective AgentsHematologic NeoplasmsNeutropeniaClostridium InfectionsSepsisHumansAnti-Bacterial AgentsRetrospective StudiesNeoplasm Recurrence, LocalGram-Negative Bacteria

Stichwörter der Autor:innen

Gram negativeantimicrobial stewardshipdurationimmunocompromisedneutropeniasepsis

Substanzen

Anti-Bacterial AgentsAnti-Infective Agents

Autor:innen und Institutionen

  • Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Clinical Trials & Biostatistics, Department of Quantitative Health Sciences, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Ranganath, N., Yetmar, Z. A., McCandless, A. R., Rivera, C. G., Lahr, B. D., Tande, A. J., & Shah, A. S. (2023). Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation. Transplant Infectious Disease. https://doi.org/10.1111/tid.14085

Vancouver

Ranganath N, Yetmar ZA, McCandless AR, Rivera CG, Lahr BD, Tande AJ, et al. Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation. Transplant Infectious Disease. 2023. doi:10.1111/tid.14085

BibTeX
@article{Ranganath2023,
  author = {Ranganath, Nischal and Yetmar, Zachary A and McCandless, Audrey R and Rivera, Christina G and Lahr, Brian D and Tande, Aaron J and Shah, Aditya S},
  title = {Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14085}
}
Kostenlos starten →